Michael Retsky (PhD in Physics from University of Chicago) made a career change to cancer research thirty years ago. . He was Prof of Biology at University of Colorado and Visiting Prof of Medical Oncology at University of Texas. He is Research Associate at Harvard TH Chan School of Public Health and Honorary Reader at University College London. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. Retsky is Editor of a Springer-Nature book on a breast cancer project published July 2017. After diagnosis of stage IIIc colon cancer in 1994, he was the first person to use what is now called metronomic adjuvant chemotherapy. He is a founder and for 10 years was on the Board of Directors of the Colon Cancer Alliance. He has published more than 70 papers in physics and cancer.
Research interest A bimodal pattern of hazard of relapse among early stage breast cancer patients has been identified in multiple databases from US, Europe and Asia, studying these data to determine if this can lead to new ideas on how to prevent relapse in breast cancer, Using computer simulation and access to a very high quality database from Milan for patients treated with mastectomy only.